Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,404 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Measuring antiplatelet drug effects in the laboratory.
Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Harrison P, et al. Thromb Res. 2007;120(3):323-36. doi: 10.1016/j.thromres.2006.11.012. Epub 2007 Jan 17. Thromb Res. 2007. PMID: 17239428 Review.
Beware of being caught on the rebound.
Lordkipanidzé M, Harrison P. Lordkipanidzé M, et al. J Thromb Haemost. 2011 Jan;9(1):21-3. doi: 10.1111/j.1538-7836.2010.04125.x. J Thromb Haemost. 2011. PMID: 21210949 No abstract available.
Platelet hyperactivity and risk of recurrent thrombosis.
Harrison P, Keeling D. Harrison P, et al. J Thromb Haemost. 2006 Dec;4(12):2544-6. doi: 10.1111/j.1538-7836.2006.02249.x. Epub 2006 Oct 5. J Thromb Haemost. 2006. PMID: 17026648 No abstract available.
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Hayward CP, et al. J Thromb Haemost. 2006 Feb;4(2):312-9. doi: 10.1111/j.1538-7836.2006.01771.x. J Thromb Haemost. 2006. PMID: 16420557 Review.
Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
Spronk HMH, Padro T, Siland JE, Prochaska JH, Winters J, van der Wal AC, Posthuma JJ, Lowe G, d'Alessandro E, Wenzel P, Coenen DM, Reitsma PH, Ruf W, van Gorp RH, Koenen RR, Vajen T, Alshaikh NA, Wolberg AS, Macrae FL, Asquith N, Heemskerk J, Heinzmann A, Moorlag M, Mackman N, van der Meijden P, Meijers JCM, Heestermans M, Renné T, Dólleman S, Chayouâ W, Ariëns RAS, Baaten CC, Nagy M, Kuliopulos A, Posma JJ, Harrison P, Vries MJ, Crijns HJGM, Dudink EAMP, Buller HR, Henskens YMC, Själander A, Zwaveling S, Erküner O, Eikelboom JW, Gulpen A, Peeters FECM, Douxfils J, Olie RH, Baglin T, Leader A, Schotten U, Scaf B, van Beusekom HMM, Mosnier LO, van der Vorm L, Declerck P, Visser M, Dippel DWJ, Strijbis VJ, Pertiwi K, Ten Cate-Hoek AJ, Ten Cate H. Spronk HMH, et al. Thromb Haemost. 2018 Feb;118(2):229-250. doi: 10.1160/TH17-07-0492. Epub 2018 Jan 29. Thromb Haemost. 2018. PMID: 29378352 Free PMC article.
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Bethel MA, Harrison P, Sourij H, Sun Y, Tucker L, Kennedy I, White S, Hill L, Oulhaj A, Coleman RL, Holman RR. Bethel MA, et al. Diabet Med. 2016 Feb;33(2):224-30. doi: 10.1111/dme.12828. Epub 2015 Jul 14. Diabet Med. 2016. PMID: 26043186 Clinical Trial.
Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease.
Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM. Kunicki TJ, et al. Thromb Haemost. 2009 Jan;101(1):123-33. Thromb Haemost. 2009. PMID: 19132198 Clinical Trial.
The ASA non-responsive cohort had significantly increased whole blood platelet counts (p = 0.03) and plasma von Willebrand Factor antigen levels (p < 0.001), which likely contributes to resistance to the inhibitory effects of ASA in the PFA-100....
The ASA non-responsive cohort had significantly increased whole blood platelet counts (p = 0.03) and plasma von Willebrand Factor ant …
Measurement of the antiplatelet effects of aspirin in cerebrovascular disease.
McCabe DJ, Harrison P, Machin SJ, Watt H, Brown MM. McCabe DJ, et al. Stroke. 2004 Jun;35(6):e146-7; author reply e146-7. doi: 10.1161/01.STR.0000126474.25720.3e. Epub 2004 Apr 8. Stroke. 2004. PMID: 15073394 No abstract available.
Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry.
Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Harrison P, et al. Stroke. 2005 May;36(5):1001-5. doi: 10.1161/01.STR.0000162719.11058.bd. Epub 2005 Apr 7. Stroke. 2005. PMID: 15817896
Agreement between the RPFA and the PFA-100 and arachidonic acid induced LTA was poor (kappa=0.16, 95% CI, -0.08 to 0.39, P=0.11; and kappa=0.09 -0.12 to 0.30, P=0.32, respectively). Agreement between the 2 POC tests was also poor (kappa=0.14, -0.08 to 0.36, P
Agreement between the RPFA and the PFA-100 and arachidonic acid induced LTA was poor (kappa=0.16, 95% CI, -0.08 to 0.39, P=0.11; and …
Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM. McCabe DJ, et al. Platelets. 2005 Aug;16(5):269-80. doi: 10.1080/09537100400020567. Platelets. 2005. PMID: 16011977
There was a significant inverse relationship between plasma von Willebrand factor antigen levels and C-EPI closure times in both early and convalescent phase CVD patients (P=0.008). Mean von Willebrand factor antigen levels were significantly higher in aspirin non-responde …
There was a significant inverse relationship between plasma von Willebrand factor antigen levels and C-EPI closure times in both early and c …
2,404 results
Jump to page
Feedback